149 related articles for article (PubMed ID: 37417301)
1. Prognostic significance of heterologous component in carcinosarcoma of the gynecologic organs: a systematic review and meta-analysis.
Kim Y; Kang GH; Kim H
J Gynecol Oncol; 2023 Nov; 34(6):e73. PubMed ID: 37417301
[TBL] [Abstract][Full Text] [Related]
2. Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.
Matsuo K; Takazawa Y; Ross MS; Elishaev E; Podzielinski I; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Matsuzaki S; Baba T; Satoh S; Shida M; Nishikawa T; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Fujiwara K; Hazama Y; Kadogami D; Moffitt MN; Takeuchi S; Nishimura M; Iwasaki K; Ushioda N; Johnson MS; Yoshida M; Hakam A; Li SW; Richmond AM; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Yamaguchi K; Oishi T; Kajiwara H; Hasegawa K; Yasuda M; Kawana K; Suda K; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Wakatsuki A; Sugiyama T; Pejovic T; Nagano T; Shimoya K; Andoh M; Shiki Y; Enomoto T; Sasaki T; Fujiwara K; Mikami M; Shimada M; Konishi I; Kimura T; Post MD; Shahzad MM; Im DD; Yoshida H; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
Ann Oncol; 2016 Jul; 27(7):1257-66. PubMed ID: 27052653
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of the heterologous component in uterine carcinosarcomas.
Can B; Karataşli V; Çakir İ; Sayhan S; Hansu K; Kuru O
Rev Assoc Med Bras (1992); 2023; 69(9):e20230517. PubMed ID: 37729375
[TBL] [Abstract][Full Text] [Related]
4. Is the sarcomatous component (homologous vs heterologous) the prognostic "driving force" in early-stage uterine carcinosarcomas? A retrospective multicenter study.
Rosati A; Vargiu V; Certelli C; Arcieri M; Vizza E; Legge F; Cosentino F; Ferrandina G; Fanfani F; Scambia G; Corrado G
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6479-6488. PubMed ID: 36773091
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma.
Matsuo K; Takazawa Y; Ross MS; Elishaev E; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Baba T; Satoh S; Shida M; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Yanai S; Takeuchi S; Nishimura M; Iwasaki K; Johnson MS; Yoshida M; Hakam A; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Kajiwara H; Hasegawa K; Yasuda M; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Pejovic T; Nagano T; Sasaki T; Richmond AM; Post MD; Shahzad MMK; Im DD; Yoshida H; Enomoto T; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
Ann Surg Oncol; 2018 Sep; 25(9):2756-2766. PubMed ID: 29971677
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients.
Iwasa Y; Haga H; Konishi I; Kobashi Y; Higuchi K; Katsuyama E; Minamiguchi S; Yamabe H
Cancer; 1998 Feb; 82(3):512-9. PubMed ID: 9452269
[TBL] [Abstract][Full Text] [Related]
8. Effect of Adjuvant Therapy on Oncologic Outcomes of Surgically Confirmed Stage I Uterine Carcinosarcoma: a Turkish Gynecologic Oncology Study.
Kimyon Cömert G; Türkmen O; Boyraz G; Yalçın İ; Altın D; Karalök A; Şahin H; Taşkın S; Başaran D; Fırat Cuylan Z; Koyuncu K; Salman MC; Özgül N; Meydanlı MM; Turan T; Ortaç F; Yüce K
Balkan Med J; 2019 Jul; 36(4):229-234. PubMed ID: 30873825
[TBL] [Abstract][Full Text] [Related]
9. Prognostic features of surgical stage I uterine carcinosarcoma.
Ferguson SE; Tornos C; Hummer A; Barakat RR; Soslow RA
Am J Surg Pathol; 2007 Nov; 31(11):1653-61. PubMed ID: 18059221
[TBL] [Abstract][Full Text] [Related]
10. Effect of adjuvant therapy on the prognosis in stage I/II uterine carcinosarcoma: A meta-analysis.
Zhao F; Tan P; Wang C; Ji X; Chen A
J Obstet Gynaecol Res; 2021 Jul; 47(7):2473-2480. PubMed ID: 33913222
[TBL] [Abstract][Full Text] [Related]
11. Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages.
Rovirosa A; Ascaso C; Ordi J; Abellana R; Arenas M; Lejarcegui JA; Pahisa J; Puig-Tintoré LM; Mellado B; Armenteros B; Iglesias X; Biete A
Int J Radiat Oncol Biol Phys; 2002 Apr; 52(5):1320-9. PubMed ID: 11955745
[TBL] [Abstract][Full Text] [Related]
12. Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element.
Matsuo K; Takazawa Y; Ross MS; Elishaev E; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Baba T; Satoh S; Shida M; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Yanai S; Takeuchi S; Nishimura M; Iwasaki K; Johnson MS; Yoshida M; Hakam A; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Kajiwara H; Hasegawa K; Yasuda M; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Pejovic T; Nagano T; Sasaki T; Richmond AM; Post MD; Shahzad MMK; Im DD; Yoshida H; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
Surg Oncol; 2018 Sep; 27(3):433-440. PubMed ID: 30217299
[TBL] [Abstract][Full Text] [Related]
13. How to deal with prognostic factors and radiotherapy results in uterine neoplasms with a sarcomatous component?
Rovirosa A; Ascaso C; Ordi J; Arenas M; Valduvieco I; Lejarcegui JA; Pahisa J; Torne A; Biete A
Clin Transl Oncol; 2009 Oct; 11(10):681-7. PubMed ID: 19828411
[TBL] [Abstract][Full Text] [Related]
14. Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Ebata T; Yonemori K; Nishikawa T; Sudo K; Shimomura A; Noguchi E; Fujiwara Y; Kato T; Hasegawa K; Fujiwara K; Tamura K
Oncology; 2020; 98(10):699-705. PubMed ID: 32526764
[TBL] [Abstract][Full Text] [Related]
15. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
[TBL] [Abstract][Full Text] [Related]
16. Prognostic determinants in patients with uterine and ovarian carcinosarcoma.
Rauh-Hain JA; Shoni M; Schorge JO; Goodman A; Horowitz NS; del Carmen MG
J Reprod Med; 2013; 58(7-8):297-304. PubMed ID: 23947079
[TBL] [Abstract][Full Text] [Related]
17. SATB2 Expression Is Sensitive but Not Specific for Osteosarcomatous Components of Gynecologic Tract Carcinosarcomas: A Clinicopathologic Study of 60 Cases.
Sangoi AR; Kshirsagar M; Horvai AE; Roma AA
Int J Gynecol Pathol; 2017 Mar; 36(2):140-145. PubMed ID: 27294605
[TBL] [Abstract][Full Text] [Related]
18. Prognostic assessment of sarcomatous histologic subtypes of ovarian carcinosarcoma.
Kim HJ; Lee HM; Kim MK; Lee YK; Lee IH; Lee KH; Kim H
Obstet Gynecol Sci; 2017 Jul; 60(4):350-356. PubMed ID: 28791266
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors impacting survival in early stage uterine carcinosarcoma.
Kurnit KC; Previs RA; Soliman PT; Westin SN; Klopp AH; Fellman BM; Lu KH; Ramondetta LM; Fleming ND
Gynecol Oncol; 2019 Jan; 152(1):31-37. PubMed ID: 30414738
[TBL] [Abstract][Full Text] [Related]
20. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed müllerian tumors) supports a dominant role of the carcinomatous component.
Costa MJ; Guinee D
Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):293-9. PubMed ID: 11127921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
